Dear Aneurin Bevan University Health Board,

The Royal Osteoporosis Society is undertaking a Freedom of Information Act (FOI) request of all Trusts, Health Boards and Health and Social Care Trusts, with the aim of assessing the number of Fracture Liaison Services (FLS) that exist across the UK and the delivery of these services.

Fracture Liaison Services (FLS) systematically identify people aged 50 and older who have had a 'fragility fracture', with the aim of reducing their risk of further fractures.

Data will be used to identify how we can target future resources to ensure that all patients at risk of secondary fragility fractures and osteoporosis have access to and are referred to a FLS for further bone health assessment.

We really appreciate your help with this, especially as we understand the pressures that healthcare services are currently experiencing. Please pass the questions below on to your Fracture Liaison Service at the following hospitals or if this is not possible, please pass on to the osteoporosis clinical lead or musculo-skeletal lead for them to complete:

Nevill Hall Hospital, Royal Gwent Hospital, Ysbyty Ystrad Fawr Hospital

We ask that you please indicate your answer by marking with an “X” next to any answers that apply or by deleting all answers that do not apply. Please avoid answering by italics, underlining or bold, as these do not show up when we process your response.

Yours faithfully,

Craig Jones, Chief Executive, Royal Osteoporosis Society

Hospital name:

1. Do your patients over 50 years old have access to a Fracture Liaison Service (FLS)?
a. Yes
b. No commissioned FLS but pathway for bone health management of fracture patients
c. No commissioned FLS and no pathway for bone health management of fracture patients

If you answered ‘no’ (b or c) please move on to question 15.

2. Is your FLS based in secondary care?
a. Yes
b. No

3. For 2019, what percentage of people over 50 with a fracture were offered access to a FLS?
a. (please specify:)

4. For 2019, what percentage of people referred to FLS received an assessment within 12 weeks of fracture diagnosis?
a. (please specify:)

5. For 2019, for those patients receiving osteoporosis drug treatment what percentage were reviewed for follow up 16 weeks from fracture?
a. (please specify:)

6. For 2019, For those patients receiving osteoporosis drug treatment what percentage were reviewed for follow up 52 weeks from fracture?
a. (please specify:)

7. For 2020, what percentage of people over 50 with a fracture were offered access to a FLS?
a. (please specify:)

8. For 2020, what percentage of people referred to FLS received an assessment within 12 weeks of fracture diagnosis?
a. (please specify:)

9. For 2020, for those patients receiving osteoporosis drug treatment what percentage were reviewed for follow up 16 weeks from fracture?
a. (please specify:)

10. For 2020, For those patients receiving osteoporosis drug treatment what percentage were reviewed for follow up 52 weeks from fracture?
a. (please specify:)

11. Is this a permanent service funded by a sustainable source? (e.g., commissioning, health board/trust funded)
a. Yes
b. No
c. partially (please specify:)

12. Do you take part in a national FLS audit? (e.g. FLS-DB)
a. Yes
b. No

13. Please state the name and contact details of the Clinical Lead for this service
a. (please specify)

14. Are there any areas of support you would like further information/support from the ROS? E.g., Clinical Standards, KPIs, Service Improvement / Patient Information etc
a. (please specify:)

For those that answered ‘no’ to having an FLS (question 1).

15. What are the reasons you do not have an FLS, or access to an FLS for your patients?
a. (please specify:)

16. Have you tried to establish a FLS previously?
a. Yes
b. No
c. We are in the process of developing a FLS

17. What has been the barrier/obstacles to implementing a FLS?
a. (Please specify:)

18. If you have not tried to establish a FLS previously, why not?
a. (Please specify)

19. Do you have an osteoporosis service?
a. Yes
b. No

20. Do you have a DXA (bone density scanning) service?
a. Yes
b. No

21. Please state the name and contact details of the Clinical Leads for osteoporosis, rheumatology or musculo-skeletal, services
a. (please specify)

22. Are there any areas of support around FLS that you would like further information/support on from the ROS? E.g. patient info, Clinical Standards, KPIs, Service Improvement / Patient Information etc
a) (please specify)